Merck hit its second roadblock in a week, following the failure of its Lynparza trial with negative results in KEYNOTE-412, a phase 3 trial of Keytruda (pembrolizumab) in patients with unresected locally advanced head and neck squamous cell carcinoma.
Source: Drug Industry Daily